A study published last week by the journal European Neurology has found that the long-term use of Sativex, a spray made from the cannabis plant (one part THC, one part CBD), is effective in treating multiple sclerosis spasticity.
According to researchers, the study’s objective was to “provide long-term data on clinical outcomes, tolerability, quality of life and treatment satisfaction for MSS [multiple sclerosis spasticity] patients receiving nabiximols [Sativex] in routine care.”
Researchers used an “observational, prospective, multi-centre 3-month non-interventional study”, which included 52 patients and a 12-month analysis. “Structured documentation forms, questionnaires and validated instruments” were used for data collection.
“The mean spasticity numerical rating scale (NRS, 0-10) score decreased significantly from 6.0 ± 1.8 points at MOVE 2 baseline to 4.8 ± 1.9 points after 1 month and remained on this level after 12 months (4.5 ± 2.0 points); in patients classified as ‘initial responders’ (≥20% NRS improvement after 1 month) similar results were found (baseline: 6.3 ± 1.4 points; after 1 month: 4.0 ± 1.0 points; after 12 months: 4.3 ± 1.9 points)”, claims researchers. “The majority of patients (84%) did not report adverse events.”
In conclusion, patients found that; “Real-life data confirm the long-term effectiveness and tolerability of nabiximols for the treatment of resistant MSS in everyday clinical practice.”
The full study can be found by clicking here.